In vitro susceptibility test of Xiao’er Feiye Kechuan Oral Solution to Mycoplasma pneumoniae

Ran Wei, MSa, Haiwei Dou, MDb, Liangyu Wang, MSb, Dan Li, MDa, Xiujun Tian, MDa, Jingyi Li, MDb, Shaogang Li, MSb, Deli Xin, BSa,∗

Abstract

The aim of this study was to evaluate the inhibitory effect of antibiotics and Xiao’er Feiye Kechuan Oral Solution on Mycoplasma pneumoniae (MP) clinical isolates.

Twenty clinical isolates containing A-to-G transition at position 2635 and 10 clinical isolates without mutations in 23S rRNA V regions were randomly selected. The international standard strain FH was chosen as control strain. The minimum inhibitory concentration (MIC) of macrolide, quinolones, tetracycline, and Xiao’er Feiye Kechuan Oral Solution to MP clinical isolates were performed using broth microdilution method.

In vitro antibiotic susceptibility test of MP clinical isolates showed that MP showed high resistance to macrolide antibiotics (erythromycin and azithromycin); MIC of both were more than 64 µg/mL. The MICs of erythromycin and azithromycin for clinical isolates without mutations in 23S rRNA V regions were ≤0.5 µg/mL. The MICs of tetracycline and levofloxacin for all clinical isolates were ≤2.0 µg/mL and ≤1.0 µg/mL, respectively. The MIC of Xiao’er Feiye Kechuan Oral Solution was 13.828–6.914 mg/mL.

In vitro, the drug resistance of MP to macrolide antibiotics is higher, MP clinical isolates are sensitive to tetracycline and levofloxacin, and Xiao’er Feiye Kechuan Oral Solution also has a certain inhibitory effect on the macrolide-resistant MP.

Abbreviations: ATCC = American Type Culture Collection, CFU = colony-forming units, MIC = minimum inhibitory concentration, MP = Mycoplasma pneumoniae.

Keywords: antibiotic susceptibility test, Mycoplasma pneumoniae, Xiaoer Feiye Kechuan Oral Liquid

1. Introduction

Mycoplasma pneumoniae (MP) is the smallest prokaryotic microorganism between bacteria and viruses that can grow in lifeless medium. It is one of the most important pathogens of community-acquired pneumonia in children and accounts for 10% to 40%.[1] MP has no cell wall and is naturally resistant to antibiotics that act on the cell wall; however, it is sensitive to antibiotics that inhibit or interfere with protein synthesis and DNA replication, such as macrolide antibiotics, quinolones, tetracyclines, and so on. Tetracycline drugs, such as minocycline and doxycycline, can cause tooth coloring and enamel dysplasia, may inhibit the growth of infants and children, and are prohibited in the late pregnancy and children younger than 8 years. Quinolones can cause abnormal cartilage development, are prohibited in pregnant women, breast-feeding women, and children, and should be used with caution in children younger than 18 years. Therefore, macrolides were the most commonly used drugs for the treatment of MP infection in children.

However, since the first isolation of MP-resistant macrolide antibiotics in Japan in 2001,[2] China, France, the United States, and Germany have reported the isolation of MP resistant to macrolide antibiotics in clinical specimens of children and adult. The resistance rate of MP was 3% in Germany, increased from 5% to 30% in Japanese from 2002 to 2006, was >80% in children and was about 69% in adult of China.[3–5] Recently, many studies have reported that the effectiveness of macrolide antibiotic-resistant MP infection has led to the decrease in the effectiveness of the original macrolide antibiotics, and the time of fever and coughing is longer than those of children with sensitive MP infection. In addition, it has been reported that MP is resistant to macrolides antibiotics, causing the increase of incurable or severe pneumonia.[6–8]

To view the current situation, especially in China, it is urgent to actively seek effective therapeutic drugs and treatment plans. Chinese herbal medicine has been used in the treatment of various infectious diseases for thousands of years. Furthermore,
the multicenter clinical studies have also found that children with MP infection treated with Xiao’er FeiKechuan Oral Solution had faster improvement of clinical symptoms compared with patients without traditional Chinese medicine\(^{9,10}\). Xiao’er FeiKechuan Oral Solution has been used for the treatment of MP pneumonia clinically in China for many years. In vitro, the drug resistance of MP to macrolide antibiotics is higher, MP clinical isolates are sensitive to tetracycline and levofloxacin, and Xiao’er FeiKechuan Oral Solution also has a certain inhibitory effect on the macrolide resistant MP.\(^{11}\) The purpose of this article was to determine the minimum inhibitory concentration (MIC) of macrolides, tetracyclines, quinolones, and Xiao’er FeiKechuan Oral Solution for clinical isolates of MP in vitro, which may provide data support for the treatment of MP infection, clinical rational use of drugs.

2. Materials and methods

2.1. Identification of MP clinical isolates

This study was approved by the ethics committee of Beijing Friendship Hospital, Capital Medical University, Beijing Tropical Medicine Research Institute and conducted according to the Helsinki Declaration. The MP clinical isolates were the strains stored in our laboratory in 2016. The international standard strain FH (ATCC15531), purchased from the American Type Culture Collection (ATCC) of United States, was chosen as the control strain. Sample DNA was extracted in strict accordance with the instructions of the genome extraction kit (Kangwei century biotechnology co., LTD. Universal type column genome extraction kit, CW2298S, 40137). Then, the sample DNA was amplified by the quantitative real-time polymerase chain reaction designed by the laboratory.\(^{11}\) The PCR-positive products were sequenced, completed by Yingweijie trading co., LTD., and then compared with the MP standard strain M129 gene sequence in NCBI database.

2.2. Drug sensitivity test

2.2.1. Culture medium configuration. PPLO basal medium (\(S\)) consists of 50 mL/L newborn calf serum, 10 g/L fresh yeast extract, 0.02 g/L phenol red indicator, 10 g/L glucose and penicillin \(5 \times 10^4\) IU/100 mL.

2.2.2. Preparation of strain. The DNA samples amplified by MP clinical isolates were sequenced and analyzed. Twenty clinical isolates containing A-to-G transition at position 2063 and 10 clinical isolates without mutations in 23S rRNA V regions were randomly selected. Then, 0.2 mL bacteria solution were inoculated on the surface of solid culture medium and cultured in a humidified 5\% CO\(_2\) incubator at 37° C. The colony was observed under the microscope every day, and the colony-forming unit (CFU) was counted.

Preparation of drug macrolide was done with following: erythromycin (No.130307), azithromycin (No.130352), tetracycline (No. 130306); quinolone:levofloxacin (No.130455). All of the above drugs are purchased from the China Food and Drug Verification Research Institute. Xiao’er FeiKechuan Oral Solution (drug approval Z10950080) was developed by Sunflower Pharmaceutical Group Co., Ltd. (Heilongjiang, China). A certain amount of antibiotics was diluted with medium into 2048 \(\mu\) g/mL, 1024 \(\mu\) g/mL, 512 \(\mu\) g/mL, 256 \(\mu\) g/mL, 128 \(\mu\) g/mL, 64 \(\mu\) g/mL, 32 \(\mu\) g/mL, 16 \(\mu\) g/mL, 8 \(\mu\) g/mL. Furthermore, Xiao’er FeiKechuan Oral Solution was also diluted with medium into 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, 1:256, and 1:512.

2.2.3. Broth microdilution. The experimental group consisted of 30 MP clinical isolates, including 20 MP mutant strains and 10 Mycoplasma pneumoniae clinical isolates without mutations in 23S rRNA V regions. The control group was standard strain FH. The MIC of the drug to MP clinical isolates was measured by broth microdilution. The bacterial liquid was diluted into \(1 \times 10^3\) CFU/mL and cultured in a humidified 5\% CO\(_2\) incubator at 37° C for 2 hours. The experimental hole, positive control, negative control, and drug control were established. Two compound holes were set for each hole. The paraffin-sealed reaction plate was in a humidified 5\% CO\(_2\) incubator at 37° C for daily observation and recording results.

3. Result

The MP clinical isolates were determined as MP positive according to the amplification curve and dissolution curve (Figure 1), Ct value \(\leq 38\), Tm value consistent with the positive control. The sequence of PCR-positive products was compared
with the 23S rRNA gene sequences of standard strains, which was already registered in NCBI database, as shown in Figure 2.

According to the criteria of resistance to clinical use of MP antibiotics (Table 1) that published by the Clinical and Microbiological Standardization Committee (CLSI) in 2011,[12] the strain whether resistance to drug resistance was determined. MP standard strain FH was sensitive to macrolides, quinolones, and tetracycline antibiotics; the clinical isolates with A-to-G transition at position 2063 were resistant to erythromycin and azithromycin, and MP clinical isolates without mutations in 23S rRNA V regions were sensitive to erythromycin and azithromycin; MP clinical isolates were sensitive to tetracycline and levofloxacin. Children are sensitive to tetracycline and levofloxacin. The MIC of Xiao’er Feire Kechuan Oral Solution for MP clinical isolates and standard strains was 13.828–6.914 mg/mL. The drug sensitivity test in vitro was repeated 3 times; the results were shown in Table 2.

4. Discussion

MP infection occurs mostly in densely populated areas, and erupted once every 3 to 7 years. Its incidence is seasonal and occurs frequently in autumn. It has a slow onset, fever, paroxysmal irritating cough, and a small amount of mucous or mucopurulent sputum (occasionally bloody phlegm) and other symptoms. For MP patients, signs of the lungs are not obvious, but it is easy to cause multiple systems outside the lungs, which can also threaten life or death. MP occurs in children or adolescents, accounting for 15% to 30% of the total number of pneumonia, and the prevalence can be as high as 40% to 60%. [13]

MP has special affinity for respiratory epithelial cells, is resistant to penicillin, and is highly sensitive to macrolides such as erythromycin. Drugs for treatment of MP infection mainly include macrolides, tetracycline, and fluoroquinolones. Among them, macrolide is the safe and effective antibiotic for the treatment of respiratory diseases. Erythromycin, as the first generation of macrolide antibiotics discovered in 1952,[14] is widely applied and is the first choice for the treatment of mycoplasma infection. However, it has the disadvantage of being unstable to acid, incomplete oral absorption, and leading to gastrointestinal reactions. Then, in 1980s the second-generation macrolide antibiotics, represented by azithromycin, roxithromycin, and clarithromycin, were developed.[15] Azithromycin overcomes the deficiency of erythromycin to acid instability, improves the bioavailability, prolongs the half-life, reduces the dosage, and maintains good antibacterial activity.[16] In addition, especially in China, Chinese herbal medicine has been used in the treatment of various infectious diseases for thousands of years. In this study, to provide data and ideas for the treatment of MP infection, the in vitro inhibition of MP by antibiotics and Xiao’er Feire Kechuan Oral Solution was discussed.

In this study, the MP clinical isolates with A-to-G transition at position 2063 were all resistant to erythromycin and azithromycin; the MP clinical isolates without mutations in 23S rRNA V regions were sensitive to erythromycin and azithromycin. In vitro antibiotic susceptibility test of MP clinical isolates showed that MP showed high resistance to macrolide antibiotics (erythromycin and azithromycin); MICs of both were >64 mg/mL, which were basically consistent with the previous reports.[17,18] In this study, 30 clinical isolates of MP were sensitive to tetracycline and levofloxacin, which were also consistent with the previous studies that reported the emergence of MP clinical resistant strains to tetracycline.[19]

The main components of Xiao’er Feire Kechuan Oral Solution include anemarrhena, honeysuckle, glycyrrhiza, and other traditional Chinese medicine. Among them, honeysuckle, astragalus, and forsythia can effectively inhibit the growth of pathogenic microorganisms and obstruct the synthesis of the bacterial protein; ophiopogon and anemarrhena have the effect of nourishing yin and moistening the lung, especially for the lung infection of the children; glycyrrhiza, ephedra, and almond can clear the lung heat and have the effect of spreading the lung and relieving asthma and removing evil spirits.[20] In this study, the results showed that Xiao’er Feire Kechuan Oral Solution in children had the effect of inhibiting the growth of mutant and wild type of clinical isolates in vitro. Some multicenter clinical studies showed that Xiao’er Feire Kechuan Oral Solution has a

Table 1

Antimicrobial drug resistance standard of MP (µg/mL).

| Antibacterial drug | Sensitivity (S) | Intermediates (I) | Resistant (R) |
|--------------------|----------------|------------------|--------------|
| Erythromycin       | ≤0.5           | 0.5–<1.0         | >1.0         |
| Azithromycin       | ≤0.5           | 0.5–<1.0         | >1.0         |
| Tetracycline       | ≤2.0           | —                | —            |
| Levofloxacin       | ≤1.0           | —                | —            |

MP = Mycoplasma pneumonia.

Table 2

MIC of MP in vitro.

| Drug                        | With A-to-C transition at position 2063 | Without mutations in 23S rRNA V regions | Standard strain FH |
|-----------------------------|-----------------------------------------|----------------------------------------|-------------------|
| Azithromycin, µg/mL         | 64–128                                  | 0.003–0.008                            | 0.003             |
| Erythromycin, µg/mL         | 64–256                                  | 0.008–0.0016                           | 0.008             |
| Levofloxacin, µg/mL         | 0.4–8.0                                 | 0.4–8.0                                | 0.4               |
| Tetracycline, µg/mL         | 0.1–0.2                                 | 0.1–0.2                                | 0.2               |
| Xiao’er Feire Kechuan       | 13.8–6.9                                | 13.8–6.9                               | 13.8–6.9          |
| Oral Solution, mg/mL        |                                         |                                        |                   |

MIC = minimum inhibitory concentration, MP = Mycoplasma pneumonia.
Author contributions

Conceptualization: Ran Wei, Haiwei Dou, Shaogang Li, Deli Xin.
Data curation: Ran Wei, Haiwei Dou.
Funding acquisition: Shaogang Li, Deli Xin.
Investigation: Ran Wei.
Methodology: Shaogang Li, Deli Xin.
Project administration: Liangyu Wang.
Resources: Liangyu Wang, Jingyi Li.
Software: Dan Li, Xiujun Tian.
Supervision: Liangyu Wang, Jingyi Li.
Validation: Dan Li, Xiujun Tian.
Writing – original draft: Ran Wei, Haiwei Dou, Xiujun Tian, Jingyi Li.
Writing – review & editing: Shaogang Li, Deli Xin.

References

[1] Dumke R, Schnee C, Pletz MW, et al. Mycoplasma pneumoniae and Chlamydia spp. infection in community-acquired pneumonia, Germany, 2011–2012. Emerg Infect Dis 2015;21:426–34.
[2] Okazaki N, Narita M, Yamada S, et al. Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microb Immunol 2001;45:617–20.
[3] Peuchant O, Menard A, Renaudin H, et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother 2009;64:32–8.
[4] Xin D, Shi D. Progress in antibiotic therapy for drug-resistant Mycoplasma pneumoniae infection. Chin J Appl Clin Pediatr 2013;28:1695–7.
[5] Xin D, Mi Z, Han X, et al. Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China. Antimicrob Agent Chemother 2009;53:2158–9.
[6] Suzuki Y, Itagaki T, Seto J, et al. Community outbreak of macrolide-resistant Mycoplasma pneumoniae in Yamagata, Japan in 2009. Pediatr Infect Dis J 2013;32:237–40.
[7] Lenglet A, Herrador Z, Magiorakos AP, et al. European Working Group on Mycoplasma pneumoniae s. Surveillance status and recent data for Mycoplasma pneumoniae infections in the European Union and European Economic Area, January 2012. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 2012;17.
[8] Blystad H, Anestad G, Vestrheim DF, et al. Increased incidence of Mycoplasma pneumoniae infection in Norway 2011. Euro Surveill 2012;17:20074.
[9] Wang XQ, Yang XQ. The clinical effect of traditional Chinese medicine combined with western medicine in the treatment of pediatric mycoplasma pneumonia. Clin Res Pract 2016;22:53–4.
[10] Xi D, Xu B, Zhou W, et al. Multi-center study of the combination of traditional Chinese medicine and western methods treatment in the mycoplasma pneumoniae lower respiratory infection in children. Chin J Appl Clin Pediatr 2014;29:1818–21.
[11] Hu W, Guo D, Wang H, et al. Establishment and clinical application of a new real time PCR assay for simultaneous detection of human herpesvirus-6A and human herpesvirus-6B. Int J Pediatr 2015;42:570–4.
[12] Hecht DW, Citron DM, Dzink-Fox J, et al. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard-Seven edition 2012.
[13] You SY, Jwa HJ, Yang EA, et al. Effects of methylprednisolone pulse therapy on refractory Mycoplasma pneumoniae pneumonia in children. Allergy Asthma Immunol Res 2014;6:22–6.
[14] Smith CB, Fredewald WT, Chanock RM. Shedding of Mycoplasma pneumoniae after tetracycline and erythromycin therapy. N Engl J Med 1967;276:1172–5.
[15] Houck PM, MacLehose RF, Niederman MS, et al. Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. Chest 2001;119:1420–6.
[16] Schonwald S, Gunjaca M, Kolacny-Babic L, et al. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J Antimicrob Chemother 1990;25(suppl A):123–6.
[17] Zhou Y, Zhang Y, Sheng Y, et al. More complications occur in macrolide-resistant than in macrolide-sensitive Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother 2014;58:1034–8.
[18] Liu Y, Yu X, Zhang H, et al. Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrob Agents Chemother 2009;53:2160–2.
[19] Kenny GE, Cartwright FD. Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin. Antimicrob Agents Chemother 1991;35:587–9.
[20] Wang S, Tian J, Hao H, et al. Clinical analysis of hyperactivity in children cough oral liquid in treatment of children with pneumonia. Modern Chinese Clinical Medicine 2004;11:3–5.